FOLFOX plus FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma

Rapid Reactions

The current standard of care for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma is doublet platinum or taxane-based therapies. The current phase 2, single-arm, 2-stage trial conducted by the Big Ten Cancer Research Consortium (BTCRC-GI15-015) evaluated the efficacy, tolerability, and patient-reported outcomes of anthracycline-based triplets, including FOLFOX and nab-paclitaxel (FOLFOX-A) in chemotherapy-naïve unresectable, advanced gastric/GEJ adenocarcinoma; results of this trial were reported at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

In this 2-stage study, 12 patients were planned to be enrolled in stage I; stage II enrollment proceeded if ≥1 responses were achieved (treatment continued until disease progression or unacceptable toxicity if ≥4 responses were observed in stage II). The study enrolled patients with HER2-negative, chemotherapy-naïve, unresectable, advanced gastric/GEJ adenocarcinoma. Eligible patients received nab-paclitaxel (150 mg/m2), oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (2400 mg/m2) over 46 to 48 hours every 14 days. The primary efficacy end point was response rate.

A total of 39 patients were enrolled in the 2-stage study; 12 patients in stage I; following a 29% response rate in stage I, 27 patients were enrolled as planned in stage II. The median age of the study population (n = 39) was 63 years (range, 20-80 years), 29 (74%) were male.

Results of the total cohort of 39 patients that enrolled in stages I and II and started treatment with FOLFOX-A were reported. An overall response rate (ORR) of 42.9% was achieved, which exceeded the expected study target of 20%; the disease control rate was 80.0%. At median follow-up of 20 months, median progression-free survival (PFS) was 6.6 months (95% confidence interval [CI], 5.7-12.9) and the 12-month PFS rate was 27.5% (95% CI, 15.0%-50.5%); median overall survival (OS) was 10.5 months (95% CI, 8.9-21.7); the 12-month OS rate was 44.2% (95% CI, 29.7%-65.7%). There was no difference in efficacy outcomes (including ORR, PFS, and OS) between the gastric and GEJ patient cohorts.

The safety profile was as expected for the FOLFOX-A regimen. Treatment-related grade 3/4 toxicities occurred in ≥5% of patients, including peripheral sensory neuropathy (18.4%), anemia (18.4% each), decreased neutrophil count (15.8%), diarrhea (7.9%), fatigue (5.3%), nausea (5.3%), white blood cell decreased (5.3%).

Based on these results, it was concluded that the FOLFOX-A regimen was associated with a high response rate and expected toxicities and may be considered for patients with metastatic or advanced unresectable gastric, GEJ adenocarcinoma.


Benson AB, Kocherginsky M, Murtaza Kasi P, et al. A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015. Presented at: 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 20-22, 2022. Abstract 283.

FDA Approvals, News & Updates, Web Exclusives - March 8, 2019

March 08, 2019 – FDA Approvals, News & Updates

Approvals for new delivery methods for Herceptin and Cinvanti, and a new indication for Lonsurf close out the month of February in the FDA’s oncology-related activity.

Web Exclusives - March 28, 2019

The Quality–Cost Connection in Cancer Care: Lessons from Oncology Practices in Washington State

Although many quality measures exist in oncology, few efforts have been undertaken to prioritize, measure, and report quality and costs for an entire region. A recent multiyear, multistakeholder effort to characterize quality of care and costs for Washington State oncology practices revealed that increased quality may be associated with a reduced cost of care in oncology.